Abstract: We assess empirically whether foreign official development assistance (ODA) has been effective in alleviating HIV/AIDS epidemics, which figures prominently among the Millennium Development Goals. We employ a difference-in-difference-in-differences approach to identify the treatment effect of ODA specifically meant to fight sexually transmitted diseases on HIV/AIDS-related outcome variables. We do not find that ODA has prevented new infections to an extent that would have reduced the number of people living with HIV. By contrast, ODA has contributed effectively to the medical care of infected people. However, conclusive evidence on significant treatment effects on AIDS-related deaths only exists for the major bilateral source of ODA, the United States. In particular, targeted US assistance programs appear to be more effective than the activities of multilateral organizations.
Introduction
Five how it arrives at these impressive numbers. 3 Yet the specific claims of the Global Fund are in striking contrast to the general verdict of Easterly (2006) that foreign aid has done "so much ill and so little good." They also contradict Allen's (2004 Allen's ( : 1123 Nevertheless UNAIDS, the Joint United Nations Programme on HIV/AIDS, estimates that 33.4 million people were living with HIV in 2008. 5 This number was still increasing even though the number of new infections had slightly declined to an estimated 2.7 million since the peak in the mid-1990s. New infections continued to exceed the number of adult and child deaths due to AIDS of about two million in 2008.
The combination of donor generosity and persistent human suffering calls for an assessment of bold claims about the effectiveness of HIV/AIDS-related ODA. We argue in Section 2 that analyzing the effects of specific ODA items on specific outcome variables may help overcome the stalemate with respect to the effectiveness of aggregate ODA in promoting economic growth or alleviating poverty in the recipient countries. We propose a difference-indifference-in-differences (DDD) approach to identify the treatment effect of ODA specifically meant to fight sexually transmitted diseases on HIV/AIDS-related outcome variables (Section 3). While ODA has not reduced the number of people living with HIV, we find that ODA has contributed effectively to the medical care of infected people. However, conclusive evidence on significant treatment effects on AIDS-related deaths only exists for the major bilateral source of ODA, the United States (Section 4).
Assessing aid effectiveness: An alternative approach
The aid effectiveness literature has been preoccupied with the nexus between aggregate ODA and economic growth until recently. A consensus has remained elusive; even surveys on this strand of the literature come to opposite conclusions (McGillivray et al. 2006; Doucouliagos and Paldam 2009) . A more focused view on aid effectiveness may offer a way out of this stalemate. Donors typically stress the multidimensionality of their objectives, which suggests assessing the impact of specific ODA items on narrower outcome variables than economic growth. Previous examples of this more modest approach include: the effects of aid for education on school enrollment (e.g., Michaelowa and Weber 2007; Dreher et. 2008) ; the impact of aid for health on outcome variables such as infant mortality (e.g., Williamson 2008; Mishra and Newhouse 2009) ; aid for promoting democracy and better governance (e.g., Finkel et al. 2007; Busse and Gröning 2009; Kalyvitis and Vlachaki 2010) . Öhler et al. (2010) employ a DDD approach, as we will do in the following, to assess whether an innovative US aid scheme, the Millennium Challenge Corporation, was successful in fighting corruption in recipient countries.
There are very few studies assessing the links between specific ODA items and HIV/AIDS-related variables such as the prevalence and incidence of HIV and the number of deaths due to AIDS. Lieberman (2007) finds that ethnic fractionalization in recipient countries has a negative influence on the policy responses to HIV/AIDS epidemics, including the responses of foreign donors. This study addresses the allocation of ODA, rather than its effectiveness. Burns (2010) laments a dearth of funding and conceptual flaws that undermine the effectiveness of Japan's HIV/AIDS programs in Asian recipient countries. Peiffer and Boussalis (2010) We are aware of just one study whose approach is similar to ours. Bendavid and Bhattacharya (2009) The scarcity of empirical evaluations of the effectiveness of ODA in containing HIV/AIDS is surprising. Human suffering has been as severe and widespread, notably in subSahara Africa, for the fight against the pandemic to be listed among the so-called Millennium Development Goals (MDGs). MDG 6 requests the international community to "have halted by 2015 and begun to reverse the spread of HIV/AIDS" and to "achieve, by 2010, universal access to treatment for HIV/AIDS for all those who need it." Both altruistic donors being committed to alleviate the suffering in the afflicted countries as well as self-interested donors mainly concerned about security repercussions of the pandemic at home should be interested to assess the effectiveness of their ODA. 
Data and method
We assess the effects of ODA on two HIV/AIDS outcome variables: the number of AIDSrelated deaths of adults and children and the number of people living with HIV. UNAIDS provides point estimates for both variables covering a large number of countries and the period 1990-2007. 7 The number of AIDS-related deaths should decline if ODA is effective in 6 For example, the United States has considered the HIV/AIDS pandemic to be a national security issue since the late 1990s; see Allen (2004) Apart from ODA effects on AIDS-related deaths, we therefore present estimation results only for the number of people living with HIV. ODA could be considered to be particularly effective if the impact on both outcome variables were significantly negative.
11
The data on ODA are drawn from the OECD's Creditor Reporting System (CRS).
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The CRS reports HIV/AIDS-related ODA mainly under purpose code 13040, i. ). Yet we employ the sum of both purpose codes in our estimations performed below. (2010) focuses on specific HIV/AIDS interventions such as developing a vaccine from the perspective of effectively financing international public goods. For some countries and years, we take UNAIDS' lower or upper bound estimates, the average of the two (if both are available), or an estimate given by UNAIDS as "smaller than x" in order not to lose observations. We assess whether the results are sensitive to this procedure by excluding all observations for which a precise point estimate is lacking from UNAIDS in a robustness test (see below). 8 Data on potentially superior measures of effective treatment, notably the number of disability adjusted life years (DALYs) gained, are not available for a sufficiently large panel of countries and years. For a discussion of measurement, notably on DALYs, see World Bank (1999 ), Gaffeo (2003 ), and Global Fund (2009 Bank (1999: 280) argued that donors should pay particular attention to countries with "nascent" epidemics where prevention is most cost-effective; this suggests that setting the threshold too high would miss relevant observations. The 47 sample countries included in the baseline estimations are listed in Appendix C.
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The overall sample is split into two almost equally large sub-samples, the treatment and the control group. The treatment group comprises those countries for which the increase in per-capita ODA from all (bilateral and multilateral) donors was relatively high, while the control group comprises those countries for which the increase in ODA was relatively low (plus two countries for which ODA declined By applying the DDD estimator, we remove any fixed country effects (first differences) and any fixed time trends (second differences). 18 Formally, the DDD estimator for our baseline specification is as follows: , 1998 and 2003) . In this way we take into account that changes in the outcome variables may depend on their levels at the beginning of the periods of observation. Ignoring this factor may bias the effects of ODA.
Second, we include various other control variables (at the beginning of the first and second period) that may affect the changes in the outcome variables. 19 We include the countries' population as both dependent variables are defined in absolute numbers. The countries' GDP per capita may affect the dependent variables as higher average incomes provide better opportunities for costly treatment and prevention programs. Table 1 reports our baseline results with the number of people living with HIV (columns [1] [2] [3] [4] [5] and the number of AIDS-related deaths (columns 6-10) as dependent variables. We also considered the rate of HIV prevalence and the number of new infections as dependent variables. For the reasons stated in Section 3 these estimations are not shown, however. We proceed in several steps to evaluate the treatment effect of ODA. In columns (1) and (6) of Table 1 , we present the basic DDD estimations without any additional controls. In the next step, we add the number of people living with HIV in 1998 and 2003 (column 2) and, respectively, the number of AIDS-related deaths in 1998 and 2003 (column 7). In columns (3) and (8), we enter the full list of control variables introduced above, in order to account for the 20 Civil war conditions are proxied by setting a dummy variable equal to one if a major internal armed conflict (at least 1,000 battle-related deaths in one year) occurred in the recipient country during the respective period (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . 21 In the first period, the correlation between the initial level and the change in People living with HIV (AIDS deaths) amounts to 0.72 (0.64). In the second period, the correlation declines to 0.50 (0.12).
Results

Baseline results
effects of these variables on the changes in the outcome variable. In columns (4) and (9), we interact the level of the dependent variable with the dummy variable for the second period.
Finally, we interact all control variables with the second period dummy in columns (5) and (10).
The results of the basic DDD estimations differ considerably between the two outcome variables. In column (1) with the change in the number of people living with HIV as the dependent variable, the negative coefficient of Treatment * 2 nd period fails to pass conventional significance levels. In other words, there is no convincing evidence that ODA has been effective in causing a more favorable dynamic in the treatment group with respect to the change in the number of people living with HIV. It should be noted that this also holds when considering the rate of HIV prevalence, instead of the absolute number of people, as the dependent variable (not shown). The lack of convincing evidence might be attributed to the countervailing effects of ODA on this outcome variable. As noted above, effective prevention through ODA tends to reduce the number of people living with HIV, whereas effective medical care of infected persons tends to increase this number.
Indeed, the basic DDD estimation reported in column (6) of Table 1 reveals a significant treatment effect of ODA on the change in the number of AIDS-related deaths.
Note that the dynamic of AIDS-related deaths is relatively unfavorable in the treatment group when considering the first period 1998-2002, compared to the control group. 22 However, the relatively unfavorable dynamic in the treatment group disappears in the second period [2003] [2004] [2005] [2006] [2007] . In other words, no significant difference between the treatment and the control group can be observed anymore. 23 Taken together the treatment effect of ODA is significant at the ten percent level. According to this estimate, the stronger increase in ODA in the treatment group, compared to the control group, led to 16,665 fewer AIDS-related deaths, on average, in a country of the treatment group in the second period.
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The different results for the two outcome variables are hardly affected when controlling for their levels at the beginning of the first and the second period in columns (2) and (7). This is even though the changes in the outcome variables strongly depend on initial levels. Higher initial levels are associated with a higher increase (or a smaller decline) in the number of people living with HIV as well as AIDS-related deaths, both at the one percent level of significance. Yet the treatment effect of ODA remains as before -insignificant with 22 The marginal effect is significant at the five percent level. 23 Throughout this section, the marginal effects and the significance levels of variables included in interaction terms are calculated with the "margins" command of Stata 11.0. 24 The difference in the increase in ODA between the treatment and the control group amounts to 7.78 US$ per capita, on average.
respect to the number of people living with HIV, but significant (now at the five percent level) with respect to AIDS-related deaths. The major results also hold when adding the levels of a broader set of control variables at the beginning of the first and the second period. In fact, most of the additional control variables do not affect the changes in the outcome variables in columns (3) and (8) of Table 1 . The only exception is the positive impact of a larger population on the change in the number of deaths (larger increase or smaller decline).
By contrast, the interaction of the level of the dependent variable with the dummy variable for the second period proves to be relevant. The results reported in columns (4) and (9) indicate that the positive effects of the levels on the changes in the outcome variables weaken considerably in the second period. 25 Given that the levels are, on average, considerably larger in the treatment group than in the control group, we can infer that the treatment effect of ODA would be overestimated if we ignored these dynamics. This bias appears to be minor in column (4). The treatment effect of ODA changes its sign from negative to positive, but it remains insignificant at conventional levels. The bias is more pronounced in column (9) where the treatment effect of ODA with respect to AIDS-related deaths is no longer significant. In other words, we no longer find ODA to be effective in reducing the number of AIDS-related deaths once it is taken into account that the treatment and control groups differ in the level of the number of deaths and that this difference is associated with the dynamics of this outcome variable.
Apart from the levels of the dependent variables, the relevance of most other control variables continues to be weak when taking account of the dynamics of their levels between the first and second period. In column (5), the positive effect of logged GDP per capita on the number of people living with HIV in the first period implies an unfavorable dynamic for countries that were relatively rich. However, the unfavorable dynamic disappears in the second period. This may indicate that relatively rich countries were able to take advantage of their relative wealth in providing costly treatment and prevention programs. Public health expenditure appears to have reduced the increase in the number of people living with HIV, but only in the first period. Importantly, the treatment effect of ODA on this outcome variable remains insignificant. In column (10) larger countries show an unfavorable dynamic in the first period, but this effect disappears in the second period. Considering that the countries in the control group are, on average, larger than the countries in the treatment group, we can infer that the treatment effect of ODA would be underestimated if we did not consider these 25 In column (9) the effect of the level proves to be even insignificant in the second period.
dynamics. In fact, the treatment effect is, in absolute terms, larger in column (10) than in column (9). However, it still remains insignificant.
ODA from all donors: robustness tests
In Table 2 we report the results of four robustness tests. As before, the classification of the treatment and control groups is based on the increase in ODA per capita from all donors, as reported under purpose codes 13040 and 16064 in the CRS database. Once again we assess the treatment effect of ODA with regard to the number of people living with HIV and the number of AIDS-related deaths. The two periods under consideration, 1998-2002 and 2003-2007 , are also the same as before.
The first robustness test reported in columns (1) and (5) excludes 13 countries from the treatment group that have HIV prevalence rates greater than the maximum level of HIV prevalence rates in the control group, i.e., 5.8 percent (in 2003) . 26 Reducing the treatment group in this way serves to remove the considerable difference in the level of the outcome variables compared to the control group. 27 In other words, it provides an alternative to including the interactions of the level of dependent variables with the dummy variable for the second period. Importantly, this robustness test corroborates the previous finding that the treatment effect of ODA is insignificant for both outcome variables once we control for differences between the treatment and control groups in the level of the dependent variables.
The next robustness test reported in columns (2) and (6) excludes the middle range of the overall sample, i.e., the nine countries with an increase in ODA per capita between the first and the second period of more than 1.6 US$ and less than 3.2 US$. This reduces the treatment and the control group to essentially the same extent and widens the gap between the groups with regard to the increase in ODA. 28 Compared to columns (5) and (10) in Table 1 , the results are hardly affected. A minor exception is that the interaction of the level of AIDSrelated deaths with the dummy variable for the second period loses its significance in column (6) of Table 2 . Both treatment effects are insignificant once again.
Our major result also holds when restricting the estimations to sample countries located in sub-Sahara Africa (columns 3 and 7). This is not surprising as the 11 sample countries located in other regions spread across the whole spectrum as concerns the increase 26 See Appendix D for the countries in the respective treatment and control groups. 27 Now, the levels are even somewhat higher in the control group than in the treatment group: The level of the number of people living with HIV (AIDS-related deaths) amounts to 194,560 (17,430) in the treatment group and 251,013 (18,050) in the control group, on average. 28 Now, the average increase in ODA amounts to 11 US$ per capita in the treatment group. In the control group it corresponds to 0.77 US$ only.
in ODA, even though their HIV prevalence rate was relatively low and varied only modestly (Appendix C). Finally, the exclusion of observations for which an exact point estimate of the outcome variables was not available from UNAIDS does not change our results either.
Differences between major donors
So far we have separated the treatment group from the control group on the basis of the increase in total HIV/AIDS-related ODA per capita received by a developing country from all sources. Subsequently we take into account that the effectiveness of ODA may differ between major sources. 30 We also replicated the estimations with changes in the number of people living with HIV as the dependent variable. These estimations did not offer additional insights and are not reported. The results are available on request.
output variable due to a country's population, which can be observed in the case of bilateral aid only. At the same time, the results clearly show that the treatment effects presented before for ODA from all sources are driven by ODA effects in those countries receiving ODA mainly from DAC countries. The treatment effect proves to be insignificant throughout columns (6)-(10) with multilateral organizations as the major source of ODA. This finding sharply contradicts the widely held belief that multilateral ODA is more effective in promoting economic and social development, including by fighting HIV/AIDS. By contrast, the treatment effect is significantly negative in columns (1)- (3) with bilateral donors as the major source of ODA. According to these estimates, the stronger increase in ODA in the treatment group, compared to the control group, leads to 25,000-29,000 fewer AIDS-related deaths, on average, in a country of the treatment group in the second period. 31 The impact is thus more pronounced than that reported in columns (6)- (8) of Table 1 . As before in Table 1 , the treatment effect loses its significance when controlling for the dynamics in the outcome variable by the interaction of its level at the beginning of the two periods with the dummy variable for the second period (column 4). In other words, the treatment effect is overestimated once again if we do not control for these dynamics.
However, when controlling for the dynamics due to the countries' population in the full specification (column 5), the treatment effect is only insignificant at the margin. It also increases in size, compared to column (4).
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Importantly, the results in Table 3 point to striking differences when accounting for the source of ODA. It should be noted in this context that, in most countries with a particularly large increase in ODA, the funds come mainly from bilateral sources (see Appendix D). This implies that the difference in the increase of ODA between the treatment and the control group is more pronounced when bilateral donors represent the major source, compared to multilateral donors being the major source. The differences found in the effectiveness of bilateral and multilateral ODA are probably related to this pattern. In particular, bilateral donors are more likely to make a difference as they tend to focus on a few recipient countries. 33 The World Bank (1999) observed more than a decade ago already that the allocation of HIV/AIDS-related ODA across recipient countries differed between bilateral 31 Now, the average increase in ODA amounts to 11.04 US$ per capita in the treatment group. Thus, the difference in the increase in ODA between the treatment and the control group amounts to 10.07 US$ per capita, on average. 32 Note that, as in Table 1 , the treatment effect is biased downwards if we do not account for the dynamics due to the countries' population. Interestingly, the coefficients of the level of the outcome variable and of its interaction with the second period lose almost their significance when controlling for the dynamics due to the countries' population. 33 This becomes apparent when looking at the countries in the control group where HIV/AIDS-related ODA comes mainly from multilateral sources. The results shown in Table 4 indicate that the US approach was quite successful in containing the number of AIDS-related deaths. 34 Similar to the previous procedure, two criteria apply for countries in the treatment group: an increase in ODA from all sources above the median of the overall sample, and either the United States (columns 1-10) or the Global The quantitative impact increases further to about 35,000 fewer deaths when replicating the full specification with an additional requirement for countries to be included in the treatment group. In columns (6)- (10) the United States must not only be the major donor, but the recipient countries must also be on the list of PEPFAR's so-called focus countries.
The significant treatment effect of ODA in PEPFAR's focus countries is in line with the earlier findings of Bendavid and Bhattacharya (2009) . In all other respects, the results in columns (6)- (10) differ only marginally from those in columns (1)- (5) of Table 4 . This is plausible considering that the overlap between recipient countries where the United States is the major donor and the focus countries of PEPFAR is almost perfect, with Cambodia representing the only exception (Appendix D).
Finally, we show in Table 5 that the treatment effects of ODA reported in this subsection are robust to the exclusion of observations for which UNAIDS does not provide exact point estimates of the number of AIDS-related deaths. 35 Once again, multilateral ODA as well as ODA from the Global Fund proves to be ineffective. 36 Also as before, the treatment effect is significant at the five percent level and quantitatively most pronounced when the treatment group is restricted to PEPFAR's focus countries. The concentration on a few needy recipient countries appears to have helped ODA effectiveness. This is even though PEPFAR was widely criticized for earmarking a part of its funds for abstinence-only programs and refusing to cooperate with partner organizations offering counseling on abortion (e.g., Burns 2010: 160).
Summary and conclusion
We contribute to the nascent literature on the effectiveness of foreign official development assistance (ODA) that focuses on particular items of ODA meant to achieve specific effectiveness of their ODA independent of whether they are altruistically committed to 35 We report only the preferred full specification with the interactions included. 36 Note that the treatment group is identical for the estimations with all multilateral donors and the Global Fund reported in Table 5 .
alleviate the suffering in the afflicted countries, or mainly concerned about security repercussions of the pandemic at home.
We employ a difference-in-difference-in-differences ( We suspect that the concentration of PEPFAR's financial support in a few recipient countries has helped ODA effectiveness. However, it cannot be ruled out that factors other than different allocation rules are underlying the inferiority of ODA from other sources. For instance, the focus of specific programs may also play an important role. Medical care for infected people may have effects that are easier to detect in the shorter run, compared to efforts to prevent HIV infections. The striking differences in the effectiveness of ODA from different sources clearly deserve more attention in future research. (1) and (5): countries with HIV prevalence > 5.8 excluded from the treatment group; columns (2) and (6): countries with increase in ODA > 1.57 and < 3.15 excluded; columns (3) and (7): only countries in sub-Sahara Africa; columns (4) and (8) Table 2  Table 1  Table 4  Table 3 Difference in ODA, (2003-2007) minus (1998-2002) 
